Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
In Business 29 Years - Since 1980		THE CURRENT TIME at LC Labs is:

B-2777 Bimatoprost, >98%

[AGN 192024] [Latisse] [Lumigan] [Prostamide] [AGN-192024] [AGN192024]

M.W. 415.57

C25H37NO4

[155206-00-1]

M.I. 14:  1221

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 100 mg/mL; soluble in ethanol at 200 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 50-100 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

Find and View a Certificate of Analysis for this product

View the MSDS for this product

• Bimatoprost is a potent agonist at the FP prostaglandin receptor.  Balapure, A.K., Rexroad, C.E., Kawada, K., et al.  "Structural requirements for prostaglandin analog interaction with the ovine corpus luteum prostaglandin F2α receptor." Biochem. Pharmacol. 38: 2375-2381 (1989).  Lake, S., Gullberg, H., Wahlqvist, J., et al.  "Cloning of the rat and human prostaglandin F2α receptors and the expression of the rat prostaglandin F2α receptor."  FEBS Lett. 355:  317-325 (1994).

• Bimatoprost/timolol is an effective combination for decreasing intra-ocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT).  Curran, M.P. and Orman, J.S.  "Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension."  Drugs Aging 26:  169-184 (2009).

• Prophylactic use of 1 drop of bimatoprost before phacoemulsification cataract surgery significantly reduces intraocular pressure (IOP) at 24 hours postoperatively.  However, it failed to lower IOP levels significantly at 3 hours after surgery.  Unal, M. and Yücel, I.  "Effect of bimatoprost on intraocular pressure after cataract surgery."  Can. J. Ophthalmol. 43:  712-716 (2008).

• Bimatoprost increases outflow facility by activating a prostamide receptor in the trabecular meshwork.  Wan, Z., et al.  "Bimatoprost, prostamide activity, and conventional drainage."  Invest. Ophthalmol. Vis. Sci. 48:  4107-4115 (2007).

• Bimatoprost lengthens eyelashes.  Rundle, R.L.  "Drug That Lengthens Eyelashes Sets Off Flutter."  http://online.wsj.com/article/SB119543055372597359.html?mod=googlenews_wsj.

• Bimatoprost is the active ingredient in the drug sold under the trade name Lumigan® and in the cosmetic formulation sold under the trade name Latisse®.  This drug has been approved in at least one country for topical use (as eye drops) in patients with glaucoma to control the progression and in the management of ocular hypertension.  NOTE:  The bimatoprost product sold by LC Laboratories is NOT Lumigan®, and is NOT for human use.

• A CAS number previously assigned to bimatoprost, 267244-98-4, has been deleted by CAS and is no longer in use.

• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.